Exploring strategies for scaling up allogeneic natural killer cell therapy
Year: 2025
Type: article
Abstract: “...designing a scalable, closed-system manufacturing process from the outset ensures a seamless transition from clinical to commercial scale.”Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Will Rosellini, President, CytoImmune Therapeutics, about the advancements in natural killer (NK) cell therapies for cancer and autoimmune diseases. They also discuss the role of decentralized manufacturing in improving therapy accessibility.
Source: Cell and Gene Therapy Insights
Author: Will Rosellini
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4417323398
FWCI:
Cites:
Cited by:
Related to: